Nexplanon 68 MG implants
Ended Awarded Last action
- Contract number
- SPE2DR26FQHV3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $8,381
Award facts
- Contract value 100% obligated
- $8,381.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,381.40 by the Defense Logistics Agency on January 27, 2026, for the supply of Nexplanon 68 mg implants. This firm fixed-price delivery order, with an ultimate completion date of February 18, 2026, carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.
The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to supply pharmaceutical products and medical consumables to military healthcare facilities worldwide. Under this framework, DMS Pharmaceutical Group has demonstrated substantial federal contracting activity through numerous delivery orders spanning a diverse portfolio including branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The company's established performance record positions it as a critical supplier within the Department of Defense's pharmaceutical supply chain, capable of fulfilling the specialized medical requirements of military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FQHV3?
SPE2DR26FQHV3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FQHV3 worth?
The government has obligated $8,381 on SPE2DR26FQHV3.
Is contract SPE2DR26FQHV3 an order under another contract?
Yes. SPE2DR26FQHV3 is a delivery order under SPE2DR25D9759, an indefinite delivery contract.
Was contract SPE2DR26FQHV3 competed?
The extent of competition for SPE2DR26FQHV3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award